Chapter 158: Kindred Spirits
Amherst stared at David.
The pain from his thigh registered distantly — the specific quality of pain that arrived after adrenaline had been working and was being partially managed by the body's own response systems. He was aware of it in the abstract. What occupied his attention was what David had just said.
Not the pain. Not the threat. What David had said.
He wanted a virus capable of killing the Elder.
Amherst looked at David with the focused intensity of someone who has received information that is restructuring their understanding of a situation from the ground up.
"You're serious," Amherst said.
"Yes," David said.
Amherst looked at the laboratory through the observation window. He looked at the transport cases containing the Level 4 viral material. He looked at the equipment — the specific configuration of a properly equipped BSL-4 capable laboratory that the base had built at significant cost, that was here, that was available.
He looked at David.
"You don't care about the children," Amherst said slowly. He was working through it out loud. "The poliomyelitis outbreak — that's not what you're focused on. You're focused on something larger. Something that requires a weapon I can build."
"The poliovirus situation is being addressed through the channels I described," David said. "What I need from you is different."
Amherst absorbed this.
Something in his expression shifted — not toward trust, not toward relief, but toward a specific kind of professional engagement. The expression of a researcher who has been given a genuinely interesting problem.
"What is the target's vulnerability profile?" Amherst said.
"Single individual," David said. "Location: remote desert environment. Extreme heat. Isolation. The transmission pathway has to work in those conditions."
"The Elder," Amherst said.
David said nothing.
"I know who the High Table's Elder is," Amherst said. "The Illuminati Society briefed me on the High Table's structure when they brought me on. The Elder is above the Twelve Seats. He operates from a desert location — I was told it was the Sahara, but the specific geography was kept from me." He paused. "You want to deliver a targeted biological agent to an isolated desert location and eliminate a single individual without producing a vector that escapes the target environment." He paused. "That's a harder problem than mass deployment."
"I know," David said.
"It's also a more interesting problem," Amherst said.
David untied the restraints on Amherst's wrists.
Amherst looked at his freed hands.
He looked at David.
"You're going to use me and then eliminate me," Amherst said. He stated it without drama, with the flat acknowledgment of someone identifying a fact.
"When the work is done and what you know has been fully documented, you go into federal custody," David said. "You don't get laboratory access again. You spend the rest of your life in a facility with the specific security profile for biological weapons developers." He paused. "That's what happens."
Amherst looked at the laboratory.
He thought about federal custody and about what federal custody meant in practice. He thought about what the alternative to federal custody was if he declined to cooperate. He thought about the Level 4 viral material in the transport cases and about what could be done with it by someone who understood what they were doing and was given the opportunity to do it.
He stood up.
He limped toward the laboratory.
David put on the BSL-4 protective suit.
The suit process required methodical attention — the specific sequence that made the difference between adequate protection and inadequate protection was in the details of the layering and sealing. He moved through it with the care of a physician who had been trained in PPE protocols during his residency and had not forgotten the training.
Amherst was already at the primary workstation.
He worked with the focused efficiency of someone who had been doing this for a long time and was good at it. The specific movements were professional — precise, economic, the absence of wasted motion that distinguished an expert from someone who was competent.
David watched and learned.
He had been watching Amherst work for eleven minutes before Amherst spoke.
"The desert environment creates specific constraints," Amherst said, without looking up from the workstation. He was working and explaining simultaneously, the specific habit of someone who processed verbally. "Heat stability is the primary challenge. A standard viral agent's protein structure degrades above certain temperature thresholds. The Sahara surface temperature regularly exceeds what most known pathogens can survive." He paused, running a pipette with the specific practiced ease of someone whose hands had done this ten thousand times. "The solution is a heat-stable protein coat — borrowing from extremophile bacterial structure, integrating the stability mechanism into the viral capsid." He paused. "The Illuminati Society had this research direction. I worked on it for eight months before they redirected my focus to the poliovirus project."
David absorbed this.
"You can apply that research here," David said.
"I can complete it here," Amherst said. "The poliovirus project used similar modification techniques. The substrate is different but the methodology transfers." He paused. "The delivery mechanism is the harder problem. You want targeted delivery to a single location without environmental spread." He paused. "That requires a self-limiting design — the agent is viable in the target environment for a specific window and then degrades. The window has to be long enough to reach and affect the target, short enough to prevent diffusion beyond the target area."
"Can you build that?" David said.
Amherst was quiet for a moment.
"Yes," he said. "Given the materials available and the timeline you're working with — it's achievable." He paused. "It will not be a mass-deployment weapon. It will be a precision instrument. The distinction matters for what I need to build."
"The distinction is the point," David said.
Amherst looked at him briefly — the first time he'd looked directly at David since they entered the laboratory.
"You're not trying to end humanity," Amherst said.
"No," David said.
"You're trying to end the Elder," Amherst said. "One specific person. With a specific method. In a specific location." He paused. "That's surgery, not warfare."
"Yes," David said.
Amherst turned back to the workstation.
He worked in silence for several minutes.
Then: "The poliovirus candidate I gave your colleague," he said.
David waited.
"It's real," Amherst said. "The mRNA pathway. The spike protein synthesis." He paused. "I want you to know that."
David looked at him.
"Why?" David said.
Amherst was quiet for a moment.
"Because the work you're describing — the precision instrument, the surgical application — is the kind of work that requires trust between the researcher and the person directing the research," he said. "And trust requires honesty." He paused. "I'm telling you the vaccine candidate is real because I need you to understand that I can operate on terms that don't require me to deceive you." He paused. "The Illuminati Society required constant deception — their objectives and mine were never actually aligned. What you're describing is different. You need a specific technical outcome. I can produce a specific technical outcome. That's a workable arrangement."
David looked at him.
"House is verifying the vaccine candidate at each stage," David said. "If it's real, that will confirm."
"It will confirm," Amherst said.
He kept working.
Root appeared at the observation window.
She held up the tablet, showing a message from House: Stage seven intermediate confirmed clean. Candidate formulation is on track. I'm cautiously revising my assessment of what Amherst is actually doing in there.
David read it through the glass.
Root held up a second message: He appears to be making the actual vaccine. I want to be precise about "appears" — I'm not committing to certainty yet. But what's coming through the airlock is consistent with what he said at each stage. I've run four independent verifications.
David looked at Amherst working at the primary station.
He thought about what Amherst had said. About trust and honesty and the distinction between the Illuminati Society's arrangement and the current one.
He thought about what it meant that a man whose stated purpose was human extinction was apparently making a genuine vaccine for a pediatric poliovirus in a subway station laboratory in New York.
He thought about the specific human complexity of the person at that workstation — the genuine expertise, the specific moral architecture that had produced it, the way those two things coexisted without either canceling the other.
He thought about House's four independent verifications.
He sent Root a message: Tell Reese. Tell him to contact the CDC's emergency pharmacology contact about the animal model testing protocol. We need to be ready to move when House gives the final clearance.
Root nodded through the glass and moved away from the window.
Amherst worked through the night.
The vaccine candidate was completed at 4:47 AM.
House ran the final spectrometry analysis at 5:12 AM.
He appeared in the observation window at 5:31 AM with the expression of a man who has been proven wrong about something in a way he finds professionally interesting rather than personally uncomfortable.
David met him in the corridor.
"It's real," House said. "The mRNA formulation is correctly structured for the modified poliovirus spike protein. The lipid nanoparticle delivery system is optimized for pediatric immune response. It's not identical to what I would have designed — there are several choices in the formulation that are unusual but not wrong, and the unusual choices appear to reflect Amherst's specific familiarity with the modification's genomic landscape." He paused. "It's the work of someone who built the disease and knows its structure intimately. Which is exactly what it is." He paused. "I want to be clear that I'm not comfortable with what just happened. I'm also not comfortable ignoring the result." He paused. "Send it to the CDC."
"The animal model step," David said.
"I've already called Georgetown's emergency pharmacology lab," House said. "They're running an accelerated murine model protocol — six to eight hours for preliminary results. If preliminary results are clean, we move to the next tier." He paused. "The timeline for reaching the acute pediatric cases is — I know the timeline."
"Yes," David said.
"Then we move," House said. He started walking. Then he stopped. "One more thing."
David waited.
"Amherst," House said. "I'd like to talk to him."
David looked at him.
"Not about the virus," House said. "About him. What he is. How he became what he is." He paused. "I've treated patients with similar — with related psychological profiles. The specific combination of exceptional technical capability and a moral architecture that has reoriented around a catastrophic purpose. It's rare. It's not unique. And understanding it is — professionally relevant to me." He paused. "I want to understand him."
David thought about this.
"He's going into federal custody," David said. "Before that happens — yes. When the current work is done."
House nodded.
He walked toward the spectrometry equipment.
Reese was on the platform when David came out.
He was sitting on the edge with Andy at his feet — the dog had apparently relocated from Castle's vicinity sometime in the past several hours and had attached himself to the nearest person who was sitting quietly, which was currently Reese.
Reese looked up.
"House cleared it," David said.
Something in Reese's posture released.
"Georgetown is running the animal model protocol," David said. "Six to eight hours for preliminary results. If it's clean, we go to the next tier and then to the CDC's emergency distribution network."
Reese looked at the tracks below.
"He made it," Reese said.
"Apparently," David said.
Reese was quiet.
"Why?" Reese said.
"I asked him that," David said. "He said it was about the terms of the arrangement. That the Illuminati Society required constant deception because their objectives and his were never aligned, and that the work we're describing — specific technical outcome, clear terms — was a workable arrangement that didn't require deception." He paused. "I don't know if that's the complete answer. It may be that he made a decision at some point in the past several hours that I don't have full visibility into." He paused. "What I know is what House's spectrometry confirmed."
Reese thought about this.
"He saved them," Reese said. Quietly, with the specific weight of someone sitting with a fact they find genuinely difficult to process.
"Potentially," David said. "The animal model results will tell us more."
"But potentially," Reese said.
"Yes," David said. "Potentially."
Reese looked at Andy.
Andy looked at him with the attentiveness of a dog who had determined that the person he was sitting with needed something and was providing it through proximity.
"The man I let go five years ago," Reese said. "The decision I've been carrying." He paused. "It produced twenty thousand infected children. It also, apparently, produced the person who just made the vaccine that might help some of them." He paused. "I don't know what to do with both of those things being true simultaneously."
David sat down beside him on the platform edge.
He didn't say anything for a moment.
"Both things are true," David said finally. "That's all. They're both true and they both happened and they happened because of a decision you made with the information you had. The information was incomplete. The decision was made in good faith." He paused. "You can't resolve the two things into a clean narrative. They don't resolve. You carry them both."
Reese looked at the tracks.
"Harold carries things the same way," Reese said.
"Yes," David said. "He does."
"Does it get easier?" Reese said.
David thought about this honestly.
"No," he said. "You get better at carrying it. That's different from easier." He paused. "But better is real."
Reese was quiet for a long moment.
Then he stood.
"I'm going to call Harold," he said. "He should know about the candidate."
"He already knows," David said. "The Machine told him at 5:14 AM."
Reese looked at him.
"The Machine monitors everything," David said.
"Right," Reese said. He almost smiled. "I keep forgetting."
He walked toward the base interior.
Andy watched him go, then turned his attention to David, conducting his assessment of whether David also needed the proximity service.
David looked at the tracks.
He thought about Amherst in the laboratory — currently under Root's observation, the restraints back in place, the BSL-4 environment secured. He thought about the precision instrument problem, the heat-stable protein coat, the self-limiting design for a desert delivery environment.
He thought about the Elder — about the specific geography of the Sahara, about what John had described of his approach to the location, about the thermal data the Machine had pulled on the Moroccan desert in the relevant region.
He thought about what came next.
The Machine's terminal, visible through the open workstation door, produced a message:
Georgetown preliminary results: two hours ahead of schedule. The murine model shows appropriate immune response with no adverse events at the tested dose range. House says this is better than he expected. He says "significantly better," which based on my analysis of his communication patterns suggests he is impressed, which he is not often.
The CDC emergency distribution contact has been notified. They are preparing for rapid production scale-up.
The acute pediatric cases have a pathway.
David looked at the message for a moment.
He sent back: Good.
He sat on the platform edge and looked at the tracks and thought about the day ahead — the Fisk situation and the Wednesday window and the institutional backing from the Western European seat and what that changed about the operational picture, the Adjudicator and the Bowery King and whether 47 had made a decision, the Garment District facility that was still on the list, the Machine's twelve-hour timeline on the High Table seat identification.
He thought about all of it.
He picked one thing and started working on it.
End of Chapter 158
[Goal Tracker]
PS 500 → 1 Bonus Chapter
Reviews 10 → 1 Bonus Chapter
If you enjoyed it, consider a review.
P1treon Soulforger has 20+advance chapters